Mediget Teshome1, Caimiao Wei2, Kelly K Hunt1, Alastair Thompson1, Kelly Rodriguez1, Elizabeth A Mittendorf3. 1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. eamitten@mdanderson.org.
Abstract
BACKGROUND: Sentinel lymph node (SLN) dissection involves lymphatic mapping and selective removal of clinically negative lymph nodes at highest risk for harboring metastases. Lymphatic mapping is most often performed using radioisotope with or without blue dye (standard tracers). Sienna+(®), a superparamagnetic iron oxide that can be detected using the Sentimag(®) magnetometer, is an alternative mapping agent to identify SLNs that has been investigated in five clinical trials. This meta-analysis was performed to determine if Sienna+(®) is non-inferior for SLN detection when compared to standard tracers. METHODS: Five clinical trials comparing Sienna+(®) to a standard technique were identified, and data from these studies were used to determine the agreement by Kappa statistic between Sienna+(®) and standard tracers in identifying SLNs and malignant SLNs. The trials included 1683 SLNs identified in 804 patients. Data from the studies were imbalanced, therefore additional agreement indices were utilized to compare techniques. The estimated difference between the techniques was analyzed and a margin of ≤5 % was used to determine non-inferiority. RESULTS: Agreement between the Sienna+(®) and standard tracers was strong for SLN detection by patient [prevalence-adjusted bias-adjusted kappa (PABAK) 0.94, 95 % confidence interval (CI) 0.89-0.98], moderate to substantial for SLN detection by node (PABAK 0.68, 95 % CI 0.54-0.82), and strong for the detection of malignant SLNs by patient (PABAK 0.89, 95 % CI 0.84-0.95). Sienna+(®) demonstrated non-inferiority compared with standard tracers. CONCLUSIONS: The Sienna+(®) mapping agent is non-inferior to the standard method for SLN detection in patients with clinically node-negative breast cancer.
BACKGROUND: Sentinel lymph node (SLN) dissection involves lymphatic mapping and selective removal of clinically negative lymph nodes at highest risk for harboring metastases. Lymphatic mapping is most often performed using radioisotope with or without blue dye (standard tracers). Sienna+(®), a superparamagnetic iron oxide that can be detected using the Sentimag(®) magnetometer, is an alternative mapping agent to identify SLNs that has been investigated in five clinical trials. This meta-analysis was performed to determine if Sienna+(®) is non-inferior for SLN detection when compared to standard tracers. METHODS: Five clinical trials comparing Sienna+(®) to a standard technique were identified, and data from these studies were used to determine the agreement by Kappa statistic between Sienna+(®) and standard tracers in identifying SLNs and malignant SLNs. The trials included 1683 SLNs identified in 804 patients. Data from the studies were imbalanced, therefore additional agreement indices were utilized to compare techniques. The estimated difference between the techniques was analyzed and a margin of ≤5 % was used to determine non-inferiority. RESULTS: Agreement between the Sienna+(®) and standard tracers was strong for SLN detection by patient [prevalence-adjusted bias-adjusted kappa (PABAK) 0.94, 95 % confidence interval (CI) 0.89-0.98], moderate to substantial for SLN detection by node (PABAK 0.68, 95 % CI 0.54-0.82), and strong for the detection of malignant SLNs by patient (PABAK 0.89, 95 % CI 0.84-0.95). Sienna+(®) demonstrated non-inferiority compared with standard tracers. CONCLUSIONS: The Sienna+(®) mapping agent is non-inferior to the standard method for SLN detection in patients with clinically node-negative breast cancer.
Authors: Sina Shams; Kai Lippold; Jens Uwe Blohmer; Robert Röhle; Friedrich Kühn; Maria Margarete Karsten Journal: Ann Surg Oncol Date: 2020-12-01 Impact factor: 5.344
Authors: Heli Savolainen; Alessia Volpe; Alkystis Phinikaridou; Michael Douek; Gilbert Fruhwirth; Rafael T M de Rosales Journal: Nanotheranostics Date: 2019-06-06
Authors: Carmen J Gil; Martin L Tomov; Andrea S Theus; Alexander Cetnar; Morteza Mahmoudi; Vahid Serpooshan Journal: Micromachines (Basel) Date: 2019-07-16 Impact factor: 2.891
Authors: Daphne A J J Driessen; Tim Dijkema; Willem L J Weijs; Robert P Takes; Sjoert A H Pegge; Patrik Zámecnik; Adriana C H van Engen-van Grunsven; Tom W J Scheenen; Johannes H A M Kaanders Journal: Front Oncol Date: 2021-02-05 Impact factor: 6.244
Authors: Andreas Karakatsanis; Peer Michael Christiansen; Lone Fischer; Christina Hedin; Lida Pistioli; Malin Sund; Nils Ryegaard Rasmussen; Hjørdis Jørnsgård; Daniel Tegnelius; Staffan Eriksson; Kosmas Daskalakis; Fredrik Wärnberg; Christos J Markopoulos; Leif Bergkvist Journal: Breast Cancer Res Treat Date: 2016-04-27 Impact factor: 4.872